Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 25,918,714
  • Shares Outstanding, K 224,560
  • Annual Sales, $ 3,084 M
  • Annual Income, $ 399,000 K
  • 36-Month Beta 1.32
  • Price/Sales 8.29
  • Price/Cash Flow 18.96
  • Price/Book 2.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.47 +2.12%
on 05/23/17
133.67 -21.72%
on 05/02/17
-12.18 (-10.43%)
since 04/21/17
3-Month
102.47 +2.12%
on 05/23/17
135.86 -22.98%
on 03/06/17
-25.80 (-19.78%)
since 02/23/17
52-Week
102.47 +2.12%
on 05/23/17
157.02 -33.36%
on 06/02/16
-37.87 (-26.57%)
since 05/23/16

Most Recent Stories

More News
Nokia and Agilent rise; Alexion, Kirkland's fall

NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday:

A : 58.66 (+4.60%)
KIRK : 9.01 (-9.90%)
DSW : 16.21 (-8.16%)
NOK : 6.54 (+5.31%)
ALXN : 104.64 (-9.34%)
TTWO : 72.83 (+5.49%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN). Such investors...

ALXN : 104.64 (-9.34%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alexion Pharmaceuticals, Inc. - ALXN

Pomerantz LLP is investigating claims on behalf of investors of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN). Such investors are advised to contact Robert S. Willoughby at...

ALXN : 104.64 (-9.34%)
After Yesterday's Decline of 8.33%, Alexion Pharmaceuticals Offers Investors Better Value

Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $102.47 to a high of $112.65. Yesterday, the shares fell 8.3%, which took the trading range below the 3-day...

ALXN : 104.64 (-9.34%)
Alexion Announces Executive Leadership Changes

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced the following changes to its executive leadership team:

BXLT : 46.02 (-0.39%)
ALXN : 104.64 (-9.34%)
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ: ALXN) investors concerning the...

ALXN : 104.64 (-9.34%)
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

AGLE : 5.57 (-10.16%)
VVUS : 1.12 (+3.70%)
MEIP : 1.65 (+0.61%)
ALXN : 104.64 (-9.34%)
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 8.20 (+10.07%)
AKBA : 13.95 (+0.14%)
VRTX : 116.59 (-1.98%)
IONS : 45.14 (+0.85%)
REGN : 461.37 (+0.08%)
ALXN : 104.64 (-9.34%)
BIIB : 248.10 (-0.78%)
Rady Children's Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns

The Rady Children's Institute for Genomic Medicine (RCIGM) and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced a strategic partnership to accelerate the diagnosis of critically-ill...

ALXN : 104.64 (-9.34%)
Long-term Data Confirm Benefits of Treatment with Strensiq(R) (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers presented data showing that the rapid benefits of Strensiq(R) (asfotase alfa) achieved in adolescents and adults...

ALXN : 104.64 (-9.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system...

See More

Support & Resistance

2nd Resistance Point 116.77
1st Resistance Point 110.70
Last Price 104.64
1st Support Level 100.52
2nd Support Level 96.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.